V., Stornaiuolo, A., Cretella, G., Miele, A., Giannini, C., & De Simone, R
It has no approved indication, no approved dosing, and no regulated supply chain in this country
A minor inconvenience, not a catastrophe
It enrolled 751 adults and ran for 72 weeks at the maximum tolerated dose of each drug
The Injection (Subcutaneous) - Dosing: Once weekly - Bioavailability: ~100% (bypasses GI tract) - Weight loss in trials: Up to 22% at 36 weeks - Best for: Patients seeking maximum efficacy, comfortable with self-injection The Pill (Oral) - Dosing: Once daily (taken on an empty stomach, similar to Rybelsus) - Bioavailability: Lower than SC (relies on SNAC absorption technology) - Weight loss in trials: Up to 13.1% at 12 weeks (Phase 1 short duration) - Best for: Injection-averse patients, early treatment, maintenance, broader access The oral formulation will almost certainly deliver less weight loss than the subcutaneous version at equivalent treatment durations